Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy

Cancer Research

Volumn 68, Issue 8, 2008, Pages 2984-2992

  Rolle, Cleo E ^a   Carrio, Roberto ^a   Malek, Thomas R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OVALBUMIN; PROTEIN BCL 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFER; LYMPHOID CELL; LYMPHOID TISSUE; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; GENES, BCL-2; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 42349085267     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3040     Document Type: Article

References (45)

1. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
2. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5.
3. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73.
4. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.
5. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86.
6. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 1998;160:643-51.
7. Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002;20:1075-86.
8. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (1997) 2001;24:363-73.
9. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (1997) 2002;25:243-51.
10. + T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment. J Immunol 2004;172:7315-23.
11. Sussman JJ, Parihar R, Winstead K, Finkelman FD. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion. Cancer Res 2004;64:9124-30.
12. Manjunath N, Shankar P, Wan J, et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 2001;108:871-8.
13. + T cells. J Clin Invest 2005;115:1616-26.
14. + T cells. J Exp Med 2001;194:953-66.
15. + T cells confer superior antitumor immunity compared with effector memory Tcells. Proc Natl Acad Sci U S A 2005;102:9571-6.
16. + T cells. Proc Natl Acad Sci U S A 2004;101:1969-74.
17. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63.
18. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-45.
19. Rocha B, Tanchot C. CD8 T cell memory. Semin Immunol 2004;16:305-14.
20. + memory T cells. Immunol Rev 2006;211:146-53.
21. Tan JT, Surh CD. T cell memory. Curr Top Microbiol Immunol 2006;311:85-115.
22. + T cells. J Immunol 2001;167:4511-7.
23. Jin H, Gong D, Adeegbe D, et al. Quantitative assessment concerning the contribution of IL-2Rβ for superantigen-mediated T cell responses in vivo. Int Immunol 2006;18:565-72.
24. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001;98:2778-83.
25. + T cells deficient in the IL-15 receptor α-chain. J Immunol 2002;168:705-12.
26. Becker TC, Wherry EJ, Boone D, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002;195:1541-8.
27. + are more sensitive than naive cells to CD44low, Ly-6C- to TCR/CD8 signaling in response to antigen. J Immunol 1998;160:3236-43.
28. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 2000;1:47-53.
29. + T cell. Proc Natl Acad Sci U S A 2007;104:6341-6.
30. Bevan MJ, Fink PJ. The CD8 response on autopilot. Nat Immunol 2001;2:381-2.
31. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2:415-22.
32. + T lymphocyte responses. Nat Immunol 2003;4:361-5.
33. Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 2003;21:29-70.
34. Boissonnas A, Combadiere C, Lavergne E, et al. Antigen distribution drives programmed antitumor CD8 cell migration and determines its efficiency. J Immunol 2004;173:222-9.
35. + T cells. J Immunol 2000;164:3950-4.
36. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111:837-51.
37. Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature 1994;369:648-52.
38. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
39. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191-8.
40. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93.
41. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol 2001;2:957-61.
42. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
43. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
44. + melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res 2005;65:1570-6.
45. Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005;102:19051-6.